Role of Silymarin in Neuroprotection and Symptom Management in Parkinson's Disease

Launched by TANTA UNIVERSITY · May 23, 2025

Keywords

ClinConnect Summary

This clinical trial is looking at a substance called silymarin to see if it can help protect the brain and manage symptoms for people with Parkinson's disease. Parkinson's is a condition that affects movement and is caused by the loss of certain brain cells that produce a chemical called dopamine. Silymarin is known for its strong antioxidant properties, which means it can help fight damage to cells in the body. The trial aims to find out if silymarin can be beneficial for those already receiving treatment for their Parkinson's.

To participate in this study, individuals must be between 45 and 65 years old, have a diagnosis of Parkinson's disease, and currently be on medication that helps replace dopamine. The trial is not open for recruitment just yet, but it is targeted at both men and women who meet these criteria. Participants can expect to be part of a study that will explore how silymarin may help their condition, and they will be monitored throughout the process. It's important to note that there are specific health conditions that could prevent someone from joining, so potential participants should discuss their individual health situation with their doctor.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age between 45 and 65 years old
• • Both sexes
• • Patients with Parkinson's disease on dopamine replacement therapy
• • Modified Hoehn and Yahr stage, MHY 1-4 (29)
• Exclusion Criteria:
• • Subjects \< 18 years of age
• • Pregnant or breastfeeding women
• • Suspected hypersensitivity to silymarin or multivitamins
• • Advanced liver disease (e.g., ascites, bleeding esophageal varices, and hepatic encephalopathy)
• • Subjects with morbid obesity, i.e., a Body Mass Index (BMI) \> 40
• • Subjects with severe illness, e.g., multisystem failure, cancer, or poorly controlled diabetes, i.e., known diabetic with Hemoglobin A1C (HbA1C)\>7%
• • Current use of Silymarin or recent use within the past two weeks.
• • Other conditions, which, in the opinion of the investigators, make the patient unsuitable for enrollment.